Table 3.
Timing and Reason for Changing to Low-Dose Linezolid Among Patients With MDR TB Treated With Linezolid by Dosing Regimen—California, 2009–2016
| Low-Dose Linezolid Overall (Intermittent Dose and 300-mg Daily Dose Aggregate; n = 30) | Intermittent Dose of Linezolid (n = 10) | 300 mg/d of Linezolid (n = 20) | |
|---|---|---|---|
| Time on 600 mg daily linezolid before reduction, median (range), d | 121 (2–472) | 75 (14–425) | 146.5 (2–472) |
| Time on 600 mg daily linezolid before reduction of those whose dose change was due to an adverse event, median (range), d | 115.5 (2–472) | 94 (14–425) | 149 (2–472) |
| Time on 600 mg daily linezolid before reduction of those whose dose change was NOT due to an adverse event, median (range), d | 135 (14–360) | 14 (14–14)a | 144 (51–360) |
| Time on low-dose linezolid, median (range), d | 330 (12–708) | 518 (147–708) | 308 (12–640) |
| Reason for dose change | |||
| Adverse event, No. (%) | 22 (73) | 9 (90) | 13 (65) |
| Prophylactic, No. (%) | 7 (23) | 0 (0) | 7 (35) |
| Other, No. (%) | 1 (3.3) | 1 (10) | 0 (0) |
Abbreviation: MDR TB, multidrug-resistant tuberculosis.
a
There was only 1 patient in the intermittent group whose dose change was not due to an adverse event.